Note: Descriptions are shown in the official language in which they were submitted.
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
COMPOSITIONS AND METHODS FOR TREATING CANCER
CROSS REFERENCE TO RELATED APPLICATION
The present application claims the benefit of US Provisional Patent
Application Serial
Number 61/355,134, filed June 15, 2010, and US Provisional Patent Application
Serial Number
61/436,030, filed January 25, 2011, each of which is hereby incorporated by
reference in their
entirety.
FIELD OF THE INVENTION
The present invention relates to methods for treating cancer in a subject, as
well as related
compositions and kits, that employ a therapeutic agent, or a nucleic acid
sequence encoding a
therapeutic agent, selected from apolipoprotein A-1 (ApoA1), an ApoAl mimetic,
an agent that
increases expression of ApoAl, or a binding agent specific for oxidized ApoAl.
In certain
embodiments, the ApoAl or ApoAl mimetic is at least partially oxidation
resistant.
BACKGROUND OF THE INVENTION
Circulating cholesterol is carried by plasma lipoproteins. Lipoproteins are
particles of
lipid and protein that transport lipids in the blood. Low-density lipoproteins
(LDL) and high-
density lipoproteins (HDL) are the major cholesterol carriers. LDL is believed
to be responsible
for the delivery of cholesterol from the liver to extrahepatic tissues in the
body.
The term "reverse cholesterol transport" (RCT) describes the transport of
cholesterol
from extrahepatic tissues to the liver where it is catabolized and eliminated.
It is believed that
plasma HDL particles play a major role in the reverse transport process,
acting as scavengers of
tissue cholesterol. RCT consists mainly of three steps: (a) cholesterol
efflux, the initial removal
of cholesterol from various pools of peripheral cells; (b) cholesterol
esterification by the action
of lecithin: cholesterol acyltransferase (LCAT), preventing a re-entry of
effluxed cholesterol into
cells; and (c) uptake/delivery of HDL cholesterol ester to liver cells.
High levels of HDL and apolipoprotien A-1 (ApoAl), the major HDL protein, have
long
been associated with decreased risk for cardiovascular disease. ApoAl is a
single polypeptide
chain with 243 amino acid residues of known primary amino acid sequence
(Brewer et al.,
1
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
(1978) Biochem. Biophys. Res. Commun. 80:623-630). ApoAl acts as an acceptor
of cellular
cholesterol in the reverse cholesterol transport by mediating cholesterol
efflux from cells.
Each HDL particle contains at least one copy (and usually two to four copies)
of ApoAl.
ApoAl is synthesized in humans in the form of a preproapolipoprotein of 267
residues by the
liver and small intestine which is secreted as a proprotein that is rapidly
cleaved by the action of
a calcium-dependent protease to generate a mature 243 amino acid polypeptide
and secreted into
the plasma. ApoAl has been postulated to possess eight tandem repeating 22 mer
sequences and
two 11 mer sequences, most of which have the potential to form class A
amphipathic helical
structures (Segrest et al. (1974) FEBS Lett. 38:247-253). Characteristics of
the class A
amphipathic helix including the presence of positively charged residues at the
polar-nonpolar
interface and negatively charged residues at the center of the polar face
(Segrest et al. (1974)
FEBSLett. 38:247-253; Segrest et al. (1990) Proteins: Structure, Function, and
Genetics 8:103-
117).
ApoAl forms three types of stable complexes with lipids: small, lipid-poor
complexes
referred to as pre-beta-1 HDL; flattened discoidal particles containing polar
lipids (phospholipid
and cholesterol) referred to as pre-beta-2 HDL; and spherical particles
containing both polar and
nonpolar lipids, referred to as spherical or mature HDL (HDL3 and HDL2). Most
HDL in the
circulating population contain both ApoAl and ApoAll (the second major HDL
protein) and are
referred to as the Al/AII-HDL fraction of HDL. However, the fraction of HDL
containing only
ApoAl (referred to herein as Al-HDL fraction) appear to be more effective in
RCT. Certain
epidemiologic studies support the hypothesis that the Al-HDL fraction is anti-
atherogenic.
(Parra et al., 1992, Arterioscler. Thromb. 12:701-707; Decossin et al., 1997,
Eur. J. Clin. Invest.
27:299-307).
SUMMARY OF THE INVENTION
The present invention provides methods for treating cancer in a subject, as
well as related
compositions and kits, that employ a therapeutic agent, or a nucleic acid
sequence encoding a
therapeutic agent, selected from apolipoprotein A-1 (ApoAl) (or biologically
active fragment
thereof), an ApoAl mimetic, an agent that increases expression of ApoAl, or a
binding agent
specific for oxidized ApoAl. In certain embodiments, the ApoAl or ApoAl
mimetic is at least
partially oxidation resistant.
2
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
The present invention relates to a method of treating cancer in a subject. In
certain
embodiments, the methods include administering to the subject an amount of
high density
lipoprotein (HDL), apolipoprotien A-1 (ApoAl) (e.g., human ApoAl) or
biologically active
fragment thereof, and/or ApoAl mimetic (e.g., ApoAl-Milano, APL180, or D4F
peptide)
effective to prevent, suppress and/or inhibit cancer cell growth, survival,
proliferation, and/or
replication in the subject. The HDL, ApoAl, and/or ApoAl mimetic can be
administered in a
pharmaceutical composition directly to the subject or administered by
delivering an agent or
therapeutic that increases the level of HDL, ApoAl, and/or ApoAl mimetic in
the subject.
In some embodiments, the present invention provides methods of treating cancer
in a
subject comprising: administering to a subject a composition comprising a
therapeutic agent
and/or a nucleic acid sequence encoding the therapeutic agent, wherein the
therapeutic agent
comprises: i) apolipoprotein A-1 (ApoAl) or biologically active fragment
thereof, and/or ii) an
ApoAl mimetic (e.g., ApoAl-Milano, APL180, or D4F peptide), wherein the
administering is
effective to prevent, suppress, and/or inhibit cancer cell growth in the
subject.
In certain embodiments, the therapeutic agent comprises a high-density
lipoprotein
(HDL). In other embodiments, the therapeutic agent comprises
preproapoliprotein
(preproApoAl). In other embodiments, the composition is injected and/or
infused into the
subject. In additional embodiments, the nucleic acid sequence comprises an
ApoAl mRNA
sequence. In further embodiments, the nucleic acid sequence comprises an ApoAl
mimetic
mRNA sequence. In additional embodiments, the nucleic acid sequence comprises
a DNA
sequence encoding the therapeutic agent. In other embodiments, the nucleic
acid sequence
comprises an expression vector.
In particular embodiments, the present invention provides methods of treating
cancer in a
subject comprising: administering to a subject a composition comprising a
therapeutic agent,
wherein the therapeutic agent induces increased endogenous expression of
apolipoprotein A-1
(ApoAl) is the subject effective to prevent, suppress, and/or inhibit cancer
cell growth in the
subject. In certain embodiments, the therapeutic agent comprises a small
molecule compound.
In other embodiments, the therapeutic agent comprises a nucleic acid sequence
encoding the
HNF-4 gene or active portion thereof. In further embodiments, the therapeutic
agent comprises a
statin that is able to cause an increased expression of HDL or ABCA1. In other
embodiments,
the statin comprises Atorvastatin. In other embodiments, endurance exercise
training is
3
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
prescribed to raise HDL and therefore increase expression of ApoAl. In other
embodiments, the
therapeutic agent is niacin. In further embodiments, the therapeutic agent is
a fibrate that is able
to cause increased expression of HDL. In other embodiments, the fibrate is
selected from the
group consisting of. Fenofibrate, bezafibrate, gemfibrozil, and LY518674.
In certain embodiments, the present invention provides pharmaceutical
compositions for
treating cancer in a subject comprising: a therapeutically effective amount of
a therapeutic agent
and/or a nucleic acid sequence encoding the therapeutic agent, wherein the
therapeutic agent
comprises: i) apolipoprotein A-1 (ApoAl), and/or ii) an ApoAl mimetic, wherein
the
therapeutically effective amount is effective to prevent, suppress and/or
inhibit cancer cell
growth, survival, proliferation, and/or replication in the subject. In other
embodiments, the
therapeutic agent comprises a high-density lipoprotein. In additional
embodiments, the
therapeutic agent comprises preproapoliprotein (preproApoAl). In some
embodiments, the
nucleic acid sequence comprises an ApoAl mRNA sequence. In particular
embodiments, the
nucleic acid sequence comprises an ApoAl mimetic mRNA sequence. In further
embodiments,
the nucleic acid sequence comprises a DNA sequence encoding the therapeutic
agent. In other
embodiments, the nucleic acid sequence comprises an expression vector.
In some embodiments, the present invention provides methods of treating cancer
in a
subject comprising: administering to a subject at least one agent that
stimulates the cellular
receptors for HDL, the SR-B1 receptor, and/or the cellular cholesterol
transporters ABCA1 and
ABCG1. In particular embodiments, the agent comprises at least one of: a small
molecule, a
peptide mimetic, an antibodies or fragments thereof.
In further embodiments, the present invention provides methods for
characterizing a
subject's risk for cancer, comprising: a) determining the level of
dysfunctional DHL in a subject;
and b) comparing the measured level to a control value wherein an increase in
the measured level
of dysfunctional HDL compared to the control value correlates in the subject
with at least one of
lack of protection against cancers, development of tumors, tumor metastasis,
and shortened
survival time of the subject.
In some embodiments, the present invention provides methods of treating or
preventing
cancer is a subject comprising: administering to a subject a composition
comprising a binding
agent specific for oxidized ApoAl, wherein the administering is effective to
prevent, suppress,
and/or inhibit cancer cell growth in the subject. In particular embodiments,
the binding agent
4
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
comprises an antibody or antigen-binging portion thereof. In other
embodiments, the antibody is
the l OC5.2 monoclonal antibody, or an antigen-binding portion of the IOC5.2
monoclonal
antibody. In other embodiments, the binding agent comprises at least one
variable region, or at
least one CDR, from the IOC5.2 monoclonal antibody. In some embodiments, the
antibody is
the IOG1.5 monoclonal antibody, or an antigen-binding portion of the IOG1.5
monoclonal
antibody. In further embodiments, the binding agent comprises at least one
variable region, or at
least one CDR, from the lOG1.5 monoclonal antibody. In additional embodiments,
the antibody
is the 4G11.2 monoclonal antibody, or an antigen-binding portion of the 4G11.2
monoclonal
antibody. In other embodiments, the binding agent comprises at least one
variable region, or at
least one CDR, from the 4G11.2 monoclonal antibody.
In certain embodiments, the present invention provides methods of treating or
preventing
cancer is a subject comprising: administering to a subject a composition
comprising an HDL
mimetic peptide, wherein the administering is effective to prevent, suppress,
and/or inhibit
cancer cell growth in the subject. In some embodiments, the HDL mimetic
peptide is LSI-518P
from Lipid Sciences, Inc. In further embodiments, the HDL mimetic peptide is
mimetic peptide
4F (see Vakili et al., Adv Exp Med Biol. 2010;660:167-72, herein incorporated
by reference). In
certain embodiments, the HDL mimetic peptide is ATI-5261 (see, Bielicki et
al., J Lipid Res.
2010 Jun;51(6):1496-503, herein incorporated by reference). In other
embodiments, the HDL
mimetic is as shown in D'Souza et al., Circulation Research. 2010;107:217,
herein incorporated
by reference.
In an aspect of the invention, HDL, ApoAl and /or ApoAl mimetic is
administered to a
subject with or at risk of cancers including but not limited to malignant
melanoma, lung, breast,
colon, brain, kidney, bladder, prostate, pancreatic, oral, head and neck,
sarcomas, lymphomas
(B-cell and T-cell) and adrenal cancer. HDL, ApoAl, and/or ApoAl mimetics can
slow
development of tumors and tumor metastasis as well as lengthen survival time
of the subject.
The present invention further relates to a pharmaceutical composition for
treating cancer in a
subject. The pharmaceutical composition includes a therapeutically effective
amount of high
density lipoprotein (HDL), apolipoprotien A-1 (ApoAl), and/or ApoAl mimetic
effective to
prevent, suppress and/or inhibit cancer cell growth, survival, proliferation,
and/or replication in
the subject.
5
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
Another aspect of the present invention relates to a method of treating cancer
in a subject
by administering to the subject at least on agent that stimulates the cellular
receptors for HDL,
the SR-B1 receptor, and/or the cellular cholesterol transporters ABCA1 and
ABCG1. The agent
can comprise at least one of small molecules, peptide mimetics, antibodies or
fragments thereof
and be administered to the subject to protect the subject against a wide
variety of cancers
including but not limited to malignant melanoma, lung, breast, colon, brain,
kidney, bladder,
prostate, pancreatic, oral, head and neck, sarcomas, lymphomas (B-cell and T-
cell) and adrenal
cancer development as well as slow development of tumors, slow tumor
metastasis, and lengthen
survival time of the subject.
A further aspect of the invention relates to a diagnostic method for
characterizing a
subject's risk for cancer. The diagnostic method can include determining the
level of
dysfunctional HDL in a subject and comparing the measured level to a control
value. An
increase in the measured level of dysfunctional HDL compared to the control
value can correlate
with lack of protection against a wide variety of cancers including but not
limited to malignant
melanoma, lung, breast, colon, brain, kidney, bladder, prostate, pancreatic,
oral, head and neck,
sarcomas, lymphomas (B-cell and T-cell) and adrenal cancer development;
facilitate
development of tumors, tumor metastasis and shorten survival times.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a plot showing volume of tumor over time for a B 16-F l OL melanoma
tumor line
injected in mice with either low (ApoAl knockout) or high (human ApoAl
transgenic) HDL
levels. Mice (13 animals per genotype; male and female at 9 wks old) were
injected
subcutaneously on each flank with 1x105 B 16-F l OL tumor cells. Tumor volume
at the site of
injection was monitored by caliper measurements. Average tumor volume was
derived by
adding up the total (both flanks) tumor burden per mouse for each of 13 mice
per group and
dividing the number by n=26 (total injection sites). Abbreviations are as
follows: KO= ApoAl
null on C57B1/6 background, tg= human ApoAl expressing transgenic C57B1/6, Wt=
wild type
C57B1/6.
Fig. 2 is a plot showing survival of mice over time for mice with either low
(apoAl
knockout) or high (human apoAl transgenic) HDL levels injected with B16-F1OL
melanoma
tumor line. Mice (13 animals per genotype; male and female at 9 wks old) were
injected
6
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
subcutaneously on each flank with 1x105 B16-F1OL tumor cells. Abbreviations
are as follows:
KO= ApoAl null on C57B1/6 background, tg= human ApoAl expressing transgenic
C57B1/6,
Wt= wild type C57B1/6.
Fig. 3 is a graph showing tumor metastasis assessed by bioluminescent imaging
in mice
injected with B16-F1OL melanoma variant expressing firefly luciferase. Mice
(male and female
at 9 wks old) were injected subcutaneously on each flank with 1x105 B16-F1OL
FLuc (firefly
luciferase. Melanoma tumor cells and imaged using IVIS (Xenogen) imaging
system. Several
days prior to imaging mice were anesthetized with a cocktail of
ketamine:xylazine (4:1) in PBS
and shaved over their entire body to minimize the amount of light absorbed by
black fur. To
image, mice were injected intraperitoneally with 100 gl 30mg per ml of the
luciferase substrate,
D-luciferin (Xenogen)) in PBS, anaesthetized in an isoflurane chamber and then
imaged for 2
seconds. Ventral images were taken to denote metastasis and quantified using
Living Image
Software (Xenogen). Error bars denote standard error where n=8 (ApoA1KO), 11
A1Tg and 12
Wt. N.B metastasis in Wt strain is approximately 2-fold greater than in A1Tg.
Fig. 4 is a schematic illustration of biological processes for genes UP-
regulated by HDL.
Bio-informatic analyses were performed using Ingenuity Pathway Analysis
software. There
were 99 genes that were up-regulated by HDL. The number of genes associated
with each
biological process is indicated. Many genes mapped to several processes hence
the total number
in the pie chart adds up to more than 99 genes.
Fig. 5 is a schematic illustration of biological processes for genes DOWN-
regulated by
HDL. Bio-informatic analyses were performed using Ingenuity Pathway Analysis
software.
There were 269 genes that were down-regulated by HDL. The number of genes
associated with
each biological process is indicated. Many genes mapped to several processes
and several other
general processes are not included in this pie chart hence the total number in
the pie chart does
not add up to 269 genes.
Figure 6 shows that gene therapy with apoAl is protective for cancer
development
(tumor growth and metastases formation). ApoAl transgenic mice show reduced
tumor burden
(Figure 6A), growth rate (Figure 6A), and metastases (Figure 6B) formation
relative to wild type
(WT) mice. Figure 6 also shows that genetic deletion of apoAl (apoAl-KO mice)
are more
susceptible to development of tumor (Figure 6A), growth rate of tumor (Figure
6A), and
metastases formation (Figure 6B).
7
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
Figure 7A shows the mean tumor volume in mice injected with Lewis lung cancer
cells
after 48 days, and Figure 7B shows the survival percentage over time.
Figure 8 shows results from Tg, WT, and A1KO mice after being injected with
F I OLB 16 melanoma tumor cells and monitored for survival.
Figure 9 shows plasma levels of ApoAl after apoAl injection (subcutaneously)
into mice
every other day. Figure 9 shows that the plasma level of apoAl is between 75-
175 mg/dL.
Figure 10 shows results from Example 3 where human ApoAl or normal saline
(control)
was given to apoAl-KO who were injected with F1OL_B16 Melanoma Tumor cells.
Total
tumor burden and metastases were quantified by xenogen imaging. Total tumor
burden results
are shown in Figure 1OA, and metastases results are shown in Figure I OB.
Figure 11 shows the same mice described in Figure 10 at 16 days post tumor
injection.
Figure 12 shows the same mice described in Figure 10 at 21 days post tumor
injection.
Figure 13 shows a comparison by gender of the mice described in Figure 10.
Figure 14 shows survival time of the mice described in Figure 10.
Figure 15 shows the impact of giving apoAl as a therapy after the tumor growth
is
established and metastases are detectable. ApoAl injections were started one
week after tumor
injection. Overall tumor growth is shown in Figure 16a, and metastases
formation is shown in
Figure 16B.
Figure 16 shows that ApoAl is markedly more potent than ApoA2 at reducing
cancer
growth (Fig. 16A) and metastases formation (Fig. 16B).
Figure 17 shows a comparison of spleen macrophages from B16_FIOL tumor-bearing
A1KO mice and A1Tg mice. Figure 17 show results including cell number (Fig.
17A) and
F480+ cells as a percentage of splenocytes (Fig. 17B).
Figure 18A shows a cell plot of Cdl lb-PE vs. GR1-APC for A1Ko and Al Tg
derived
cells. Figure 18B shows the average percentage of cdlb+/GR1+ (MDSC) cells for
A1KO and
A1Tg derived cells. Figure 18C shows the average as a percentage of MDSC cells
for A1KO
and AITg cells.
Figure 19 shows the effect of apoAl on angiogenisis.
Figure 20 shows that animals that lack SRB 1 (both heterozygotes and
homozygotes)
showed protection from induced cancer growth, while the SRB1 containing mice
(SRB1+/+)
have a greater rate of induced tumor growth.
8
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
Figure 21 shows the results of screening various monoclonal antibodies that
target
different forms of oxapoAl against malignant melanoma human cancer biopsy
specimens.
Figure 22 shows immunohistochemistry on the human melanoma skin and normal
skin
tissue. The anti-human ox-apoAl mouse monoclonal antibody IOC5.2 was used at
10 ug/ml.
Results are shown in Figure 22, where A-C show ox-apoAl staining; D-F show
mouse IgGI
control staining, and G-I show H&E staining.
Figures 23-26 shows the results of screening one control mAb and three mAbs
shown to
be specific for oxidized apoAl against human malignant melanoma tumors. The
oxidized apoAl
specific antibodies were each shown to intensely stains multiple human
malignant melanoma
tumors but not normal biopsy. Figure 23 shows the results for Mab lOG1.5,
Figure 24 shows the
results for Mab IOC5.2, Figure 25 shows the results for Mab 4611.2, while
Figure 26 shows the
results of a Mab control antibody.
Figure 27A shows the results of Example 4 where mice deficient (SRB- I-/-) or
heterozygous (SRB-1+/-) for HDL receptor, SRB- 1, were injected with B16F1OL-
luciferase
(1x105 cells s.c., per flank) and tumor growth was monitored by IVIS Xenogen
live imaging.
Figure 27 B shows stimulation of allogenic T cell proliferation by splenic
dendritic cells (DCs)
isolated from naive or B16F1OL-luciferase tumor bearing mice of indicated
genotypes (n=
number of mice) 14 days post tumor cell injection. Data in Figure 27 C, where
n= number of
tumor injection sites, shows the terminal (day 21 post tumor injection; s.c.
bilaterally) tumor
volume measurements in B16F1OL-luciferase bearing NSG mice injected (s.c.,
away from the
site of tumor injection) every other day starting on day 1 post tumor
injection with ApoAl (20
mg/animal) or normal saline. Flow cytometry was performed on splenocytes from
mice
(n=number of animals) injected with normal saline (naive), B16F1OL-luciferase
(1x105 cells s.c.,
bilaterally) (27D) or injected with B16F1OL-luciferase cells at 4 separate
sites (1x105 cells s.c
per site) on the dorsal side (27E & F)) harvested on day 14 (D) or 12 (E & F)
post tumor
injection. Data points are mean +/-SEM.
Figure 28 shows the results of Example 4 where angiogenesis was assessed in
B16F1OL
melanoma bearing mice 7 days post tumor injection (s.c.,1x105 cells per
flank). Tumor
photographs were subjected to VESGEN analysis whereby color photomicrographs
(Figure 28A)
were converted to input vascular binary images (Figure 28B). The region of
interest (ROI)
representing the tumor mass (white in B) defined the perimeter of the tumor.
The output of
9
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
VESGEN was a series of color Generation Maps (colored vessels on black
background) in which
the largest diameter vessels were defined as G1 (red), with each subsequent
smaller generation
represented as G2 - G6 (C). Data in Figures 28 D, E, and F were generated from
panel C and
show number of blood vessels based on vessel diameter (D), total vessel area
(E) and vessel
length density (F). (G) Number of vessels feeding directly into the primary
tumor was counted
under a microscope where n= tumor injection sites.
Figure 29 shows results from Example 4 where primary subcutaneous B16FIOL
tumors
were harvested from A1KO and A1Tg tumor bearing mice (8 animals per genotype)
7 days post
injection (s.c.,1x105 cells per flank). Total tumor protein extracts were
prepared and subjected
to Western blotting. Specific protein bands were detected with Odyssey
infrared imaging system
with actin serving as loading control. Results are shown in Figure 29A. Figure
29B shows
MMP-9 activity in tumor extracts (in A) was assayed using Quickzyme assay kit
according to the
manufacturer's protocol. Pro-MMP-9 refers to total activity observed following
chemical
activation (APMA). Total activity includes the active enzyme (active MMP-9).
Figure 30 shows that HDL directly inhibits cancer cell migration and tissue
invasion
potential. Figure 30A shows the results from Example 4 where melanoma cells
were exposed to
apoAl and HDL and migration of cells was determined. Figure 30B shows the
results of
Example 4 where exposed to apoAl and HLL, and invasion of cells was
determined.
DEFINITIONS
For convenience, certain terms employed in the specification, examples, and
appended
claims are collected here. Unless defined otherwise, all technical and
scientific terms used
herein have the same meaning as commonly understood by one of ordinary skill
in the art to
which this invention belongs.
As used herein, "protein" is a polymer consisting essentially of any of the 20
amino
acids. Although "polypeptide" is often used in reference to relatively large
polypeptides, and
"peptide" is often used in reference to small polypeptides, usage of these
terms in the art
overlaps and is varied.
The terms "polynucleotide sequence," "nucleic acid sequence," and "nucleotide
sequence" are also used interchangeably herein.
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
"Recombinant," as used herein, means that a protein is derived from a
prokaryotic or
eukaryotic expression system.
The term "wild type" refers to the naturally-occurring polynucleotide sequence
encoding
a protein, or a portion thereof, or protein sequence, or portion thereof,
respectively, as it normally
exists in vivo.
The term "mutant" refers to any change in the genetic material of an organism,
in
particular a change (i.e. deletion, substitution, addition, or alteration) in
a wild type
polynucleotide sequence or any change in a wild type protein. The term
"variant" is used
interchangeably with "mutant." Although it is often assumed that a change in
the genetic
material results in a change of thee function of the protein, the terms
"mutant" and "variant"
refer to a change in the sequence of a wild type protein regardless of whether
that change alters
the function of the protein (e.g., increases, decreases, imparts a new
function), or whether that
change has no effect on the function of the protein (e.g., the mutation or
variation is silent).
As used herein, the term "nucleic acid" refers to poly nucleotides, such as
deoxyribonucleic acid
(DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be
understood to
include, as equivalents, analogs of either RNA or DNA made from nucleotide
analogs, and, as
applicable to the embodiment being described, single (sense or antisense) and
double-stranded
polynucleotides.
As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid
comprising an open reading frame encoding a polypeptide, including both exon
and (optionally)
intron sequences.
As used herein, the term "vector" refers to a nucleic acid molecule capable of
transporting another nucleic acid to which it has been linked. Preferred
vectors are those capable
of autonomous replication and/or expression of nucleic acids to which they are
linked. Vectors
capable of directing the expression of genes to which they are operatively
linked are referred to
herein as "expression vectors."
A polynucleotide sequence (DNA, RNA) is "operatively linked" to an expression
control
sequence when the expression control sequence controls and regulates the
transcription and
translation of that polynucleotide sequence. The term "operatively linked"
includes having an
appropriate start signal (e.g., ATG) in front of the polynucleotide sequence
to be expressed, and
maintaining the correct reading frame to permit expression of the poly
nucleotide sequence under
11
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
the control of the expression control sequence, and production of the desired
polypeptide
encoded by the polynucleotide sequence.
As used herein, the term "tissue-specific promoter" means a nucleic acid
sequence that
serves as a promoter, and which affects expression of the selected nucleic
acid sequence
operably linked to the promoter, and which affects expression of the selected
nucleic acid
sequence in specific cells of a tissue, such as cells of epithelial cells. The
term also covers so-
called "leaky" promoters, which regulate expression of a selected nucleic acid
primarily in one
tissue, but cause expression in other tissues as well.
"Homology" and "identity" are used synonymously throughout and refer to
sequence
similarity between two peptides or between tow nucleic acid molecules.
Homology can be
determined by comparing a position in each sequence, which may be aligned for
purposes of
comparison. When a position in the compared sequence is occupied by the same
base or amino
acid, then the molecules are homologous or identical at that position. A
degree of homology or
identity between sequences is a function of the number of matching or
homologous positions
shared by the sequences.
A "chimeric protein" or "fusion protein" is a fusion of a first amino acid
sequence
encoding a polypeptide with a second amino acid sequence defining a domain
(e.g., polypeptide
portion) foreign to and not substantially homologous with any domain of the
first polypeptide. A
chimeric protein may present a foreign domain which is found (albeit in a
different protein) in an
organism which also expresses the first protein, or it may be an
"interspecies," "intergenic," etc.
fusion of protein structures expressed by different kind of organisms.
The phrases "parenteral administration" and "administered paternterally" as
used herein
means modes of administration other than enteral and topical administration,
usually by
injection, and includes, without limitation, intravenous, intramuscular,
intraaterial, intrathecal,
intraventricular, intracapsular, intraorbital, intracarida, intradermal,
intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid,
intraspinal and transternal
injection and infusion. The compositions of the present invention may be
administered by
parenteral administration.
The phrases "systemic administration," administered systemically," "peripheral
administration," and "administered peripherally" as used herein mean the
administration of a
compound, drug or other material other than directly into the central nervous
system, such that it
12
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
enters the animal's system and, thus, is subject to metabolism and other like
processes, for
example, subcutaneous administration. The compositions of the present
invention may be
administered by systemic administration.
DETAILED DESCRIPTION
The present invention relates to compositions and methods of treating and/or
preventing
cancer in a subject. During the development of certain embodiments of the
present invention, it
was found that administration of HDL, ApoAl, and/or ApoAl mimetics to a
subject can prevent,
suppress and/or inhibit cancer survival and cancer cell proliferation as well
as inhibit and/or
suppress multiple pathways linked to cancer growth and replication. An aspect
of the invention
therefore relates to a method of treating or preventing cancer in a subject by
administering to the
subject an amount of high density lipoprotein (HDL), apolipoprotein A-1
(ApoAl) or a
biologically active fragment thereof, and/or ApoAl mimetic effective to
prevent, suppress and/or
inhibit cancer cell growth, survival, proliferation, and/or replication in the
subject.
High density lipoprotein (HDL) administered to the subject in accordance with
the
present invention can include a lipid-protein complex or derivative thereof
which when isolated
from plasma by ultracentrifugation is found in the density range of d=1.063 to
d=1.21. In one
embodiment of the invention, HDL can be isolated from human plasma and
administered to a
subject to protect against a wide variety of cancers, such as malignant
melanoma, lung, breast,
colon, brain, kidney, bladder, prostate, pancreatic, oral, head and neck,
sarcomas, lymphomas
(B-cell and T-cell) and adrenal cancer development; as well as to slow
development of tumors,
tumor metastasis and lengthens survival times. Preferably, the HDL or
derivative thereof is a
peptide or protein derivative of the sequence of ApoAl, or a peptide or
protein mimetic
functionally homologous to the active portions of ApoAl.
In one embodiment, the HDL used in accordance with the present invention is
reconstituted HDL. The term "reconstituted HDL" means HDL composed of a lipid
or lipids in
association with at least one of the apolipoproteins of HDL. The components
may be derived,
for example, from blood, or produced by recombinant technology. For example,
nascent HDL
can be prepared from ApoAl isolated from human plasma combined with a wide-
range of
phospholipids, such as from 5-100:1 molar ration of phospholipids to apoAl,
and reconstituted
into nascent HDL particle that can be administered to a subject to treat or
prevent cancer.
13
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
In another embodiment, HDL can include monomeric and multimeric HDL peptide
mimetics
that can function to allow HDL remodeling leading to greater anti-inflammatory
activity and
cholesterol efflux activity.
ApoAl administered in accordance with the present invention can include a full-
length
human ApoAl peptide or to a fragment or domain thereof comprising a class A
amphipathic
helix. In some embodiments, ApoAl can be combined with a wide-range of
phospholipids, such
as from 5-100:1 molar ratio of phospholipids to ApoA1, reconstituted into a
nascent HDL
particle, and administered to a subject to treat or prevent cancer. The ApoAl
reconstituted into a
HDL particle and administered to a subject can be protective against a wide
variety of cancers
including, malignant melanoma, lung, breast, colon, brain, kidney, bladder,
prostate, pancreatic,
oral, head and neck, sarcomas, lymphomas (B-cell and T-cell) and adrenal
cancer development,
slow development of tumors, and lengthens survival times of the subject.
In other embodiments, ApoAl can be administered in combination with a wide-
range of
phospholipids and cholesterol, such as from 5-100:1 molar ratio of
phospholipids:cholesterol:ApoAl and reconstituted into a nascent HDL
cholesterol particle. The
ApoAl reconstituted into a HDL cholesterol particle and administered to a
subject is protective
against a wide variety of cancers including, malignant melanoma, lung, breast,
colon, brain,
kidney, bladder, prostate, pancreatic, oral, head and neck, sarcomas,
lymphomas (B-cell and T-
cell) and adrenal cancer development, slow development of tumors, and
lengthens survival times
of the subject.
The ApoAl administered to a subject to treat cancer can also include ApoAl
mimetics.
The terms "mimetics of ApoAl" or "known mimetics of ApoAl," or "ApoAl
mimetics," refer to
mimetics of ApoAl that can be identified or derived from any reference and
that have ApoAl
behavior. These include mimetics of ApoAl identified in U.S. and foreign
patents and
publications.
ApoAl mimetics can include natural variants of ApoAl that are known in the
art. For
example, Weisgraber et al. has shown that cysteine can be substituted for
arginine at position 173
in a mutant ApoAl termed ApoAl-Milano (Weisgraber et al. (1983) J. Biol. Chem.
258:2508-
2513, herein incorporated by reference). ApoAl polypeptide mimetics
contemplated in the
present invention can also include polypeptides from the ApoAl forms and
variants including,
for example, apolipoprotein A-1 (Brewer et al., (1978)), apolipoprotein A-1
Milano (Weisgraber
14
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
(1983)), apolipoprotein A-1 Paris (Bielicki and Oda (2002) Biochemistry
41:2089-2096),
proapolipoprotein A-1, or any other mutant form of ApoAl known in the art
whether
synthetically formed or naturally occurring.
Alternatively, the ApoAl mimetics of the present invention can include an
amphipathic
helical peptides that closely mimic the class A amphipathic helix of human or
mouse ApoAl
peptide (i.e., mimetics of ApoAl). The term "an amphipathic helical peptide"
refers to a peptide
comprising at least on amphipathic helix (amphipathic helical domain). Certain
amphipathic
helical peptides of this invention can comprise two or more (e.g., 3, 4, 5,
etc.) amphipathic
helices.
The term "class A amphipathic helix" refers to a protein structure that forms
in an a-helix
producing a segregation of a polar and nonpolar faces with the positively
charged residues
residing at the polar-nonpolar interface and the negatively charged residues
residing at the center
of the polar face (see, e.g., Segrest et al. (1990) Proteins: Structure,
Function, and Genetics
8:103-117). Particularly preferred peptides may include greater than about 50%
amino acid
sequence identity with the polypeptide encoded by the exon encoding a class A
amphipathic
helix of human or mouse ApoAl. The peptide may be combined with a
pharmacologically
acceptable excipient (e.g., an excipient suitable for oral administration to a
mammal).
In one embodiment, the ApoAl mimetic can be resistant to oxidation when
administered to a
subject. By "resistant to oxidation" or "oxidant resistant" as used in the
specification and the
claims, it is meant the ApoAl mimetic according to the present invention has
an amino acid
sequence that is substantially similar to the amino acid sequence of ApoAl,
ApoAl fragments,
or known mimetics of ApoAl that contain at least on tryptophan and were at
least on tryptophan
residues is substituted with oxidant resistant residues, such as an oxidant
resistant peptide
residue, and for which ApoAl lipid binding an efflux activities are retained.
In another embodiment, the oxidant resistant residue of the ApoAl mimetic can
include
an aromatic peptide residue, such as phenylalanine. Examples of oxidant
resistant ApoAl
mimetics are disclosed in U.S. Patent Application No. 12/256,822, filed
October 23, 2008, which
is incorporated herein by reference in its entirety. For example, the oxidant
resistant ApoAl
mimetic can include forms of human ApoAl, such as 4WF (tryptophans [W] at
amino acids 8,
50, 72 and 108 mutated to phenylalanines [F]).
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
In another embodiment, the oxidant resistant ApoAl mimetic used to treat
cancer in a
subject can fail to activate a proinflammatory cellular reaction including
activation of nuclear
factor kappa B transcription factor, or vascular cell adhesion molecule (VCAM)
expression. For
example, it was found that oxidant resistant forms of human ApoAl that include
166 tyrosine (y)
to glutamic acid (E) or aspartic acid (D) mutations retain Lecithin-
cholesterol acyltransferase
(LCAT) binding and are capable of stimulation LCAT activity as well as fail to
activate a
proinflammatory cellular reaction including activation of nuclear factor kappa
B transcription
factor, or vascular cell adhesion molecule (VCAM) expression.
In some embodiments of the present invention, the oxidant resistant ApoAl can
include
the 4WF mutations in combination with Y166 E or D mutations and be
administered to a subject
to protect against a wide variety of cancers including, malignant melanoma,
lung, breast, colon,
brain, kidney, bladder, prostate, pancreatic, oral, head and neck, sarcomas,
lymphomas (B-cell
and T-cell) and adrenal cancer development as well as slow development of
tumors, slow tumor
metastasis, and lengthen survival times of the subject.
In certain embodiments of the invention, the ApoAl mimetic have the following
amino
acid sequence:
(SEQ ID NO: 1) DEPPQSPXDR VKDLATVYVD VLKDSGRDYV SQFEGSALGK
QLNLKLLDNX DSVTSTFSKL REQLGPVTQE FXDNLEKETE GLRQEMSKDL
EEVKAKVQPY LDDFQKKXQE EMELYRQKVE PLRAELQEGA RQKLHELQEK
LSPLGEEMRD RARAHVDALR THLAPYSDEL RQRLAARLEA LKENGGARLA
EYHAKATEHL STLSEKAKPA LEDLRQGLLP VLESFKVSFL SALEEYTKKL NTQ
wherein X is either a tryptophan residue or an oxidant resistant residue
(e.g.,
phenylalanine) and at least one of the four X's is an oxidant resistant
residue. In other examples,
at least two of the Xs of SEQ ID NO: 1 are an oxidant resistant residue, at
least three of the Xs of
SEQ ID NO: 1 are oxidant resistant residues, or all four of the Xs are oxidant
resistant residues.
In certain embodiments, the ApoAl mimetics, besides including tryptophan
substituted
wild-type or native forms of ApoA 1, can also include tryptophan substituted
natural variants of
ApoAl that are known in the art. For example, Weisgraber et al. has shown that
cysteine can be
substituted for arginine at position 173 in a mutant ApoAl termed ApoAl-Milano
(Weisgraber
et al. (1983) J. Biol. Chem. 258: 2508-2513, herein incorporated by
reference). An ApoAl
mimetic based on ApoAl-Milano can therefore include the amino sequence of SEQ
ID NO: 2.
16
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
(SEQ ID NO: 2) MKAAVLTLAV LFLTGSQARH FXQQDEPPQS PXDRVKDLAT
VYVDVLKDSG RDYVSQFEGS ALGKQLNLKL LDNXDSVTST FSKLREQLGP
VTQEFXDNLE KETEGLRQEM SKDLEEVKAK VQPYLDDFQK KXQEEMELYR
QKVEPLRAEL QEGARQKLHE LQEKLSPLGE EMRDRARAHV DALCTHLAPY
SDELRQRLAA RLEALKENGG ARLAEYHAKA TEHLSTLSEK AKPALEDLRQ
GLLPVLESFK VSFLSALEEY TKKLNTQ
wherein X is a tryptophan or an oxidant resistant residue (e.g.,
phenylalanine) and at least
one X is substituted for an oxidant resistant residue.
In another embodiments of ApoAl mimetic according to the present in invention
is based
on a known full-length mimetic of human ApoAl peptide possessing a cysteine
residue at
position 151 of the mature ApoAl (corresponding to position 175 in the
sequence SEQ ID NO:
3). The ApoAl mimetic in accordance with this example can include the amino
acid sequence of
SEQ ID NO: 3.
(SEQ ID NO: 3) MKAAVLTLAV LFLTGSQARH FXQQDEPPQS PXDRVKDLAT
VYVDVLKDSG RDYVSQFEGS ALGKQLNLKL LDNXDSVTST FSKLREQLGP
VTQEFXDNLE KETEGLRQEM SKDLEEVKAK VQPYLDDFQK KXQEEMELYR
QKVEPLRAEL QEGARQKLHE LQEKLCPLGE EMRDRARAHV DALCTHLAPY
SDELRQRLAA RLEALKENGG ARLAEYHAKA TEHLSTLSEK AKPALEDLRQ
GLLPVLESFK VSFLSALEEY TKKLNTQ;
wherein X is a tryptophan or an oxidant resistant residue (e.g.,
phenylalanine) and at least
one X is substituted for an oxidant resistant residue (e.g., phenylalanine).
In some embodiments, the ApoAl polypeptide mimetics contemplated in the
present
invention may include modified polypeptides from the ApoAl forms and variants
including, for
example, apolipoprotein A-1 (Brewer et al., (1978)), apolipoprotein A-1 Milano
(Weisgraber,(1983)), apolipoprotein A-1 Marburg, (Utermann et al., (1982) J.
Biol. Chem. 257:
501-507), apolipoprotein A-1 Paris (Bielicki and Oda (2002) Biochemistry 41,
2089-2096),
proapolipoprotein A-1, or any other mutant form of ApoA 1 known in the art
whether
synthetically formed or naturally occurring.
In other embodiments, the ApoAl mimetics of the present invention can include
an
amphipathic helical peptides that closely mimic the class A amphipathic helix
of human or
mouse ApoAl peptide (i.e., mimetics of ApoAl), wherein residues denoted by X
can include a
17
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
tryptophan residue or an oxidant resistant amino acid residue and at least one
X is an oxidant
resistant residue. The term "an amphipathic helical peptide" refers to a
peptide comprising at
least one amphipathic helix (amphipathic helical domain). Certain amphipathic
helical peptides
of this invention can comprise two or more (e.g., 3, 4, 5, etc.) amphipathic
helices.
The term "class A amphipathic helix" refers to a protein structure that forms
an a-helix
producing a segregation of a polar and nonpolar faces with the positively
charged residues
residing at the polar-nonpolar interface and the negatively charged residues
residing at the center
of the polar face (see, e.g., Segrest et al. (1990) Proteins: Structure,
Function, and Genetics 8:
103-117). Particularl peptides may include greater than about 50% amino acid
sequence identity
with the polypeptide encoded by the exon encoding a class A amphipathic helix
of human or
mouse ApoAl. The peptide may be combined with a pharmacologically acceptable
excipient
(e.g. an excipient suitable for oral administration to a mammal).
In certain embodiments, the ApoAl mimetic is a biologically active fragment
(e.g.,
reduces tumor size or other symptoms of cancer) or mimetic of ApoAl, which is
capable of
treating cancer (e.g., causing tumor size reduction), and comprises or
consists of one or more of
the following amino acid sequences:
D-X-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 4)
D-X-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 5)
D-X-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-, (SEQ ID NO: 6)
D-X-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-, (SEQ ID NO: 7)
D-X-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-, (SEQ ID NO: 8)
D-X-L-K-A-F-Y-D-K-F-F-E-K-F-K-E-F-F-, (SEQ ID NO: 9)
D-X-F-K-A-F-Y-D-K-F-F-E K-F-K-E-F-F-, (SEQ ID NO: 10)
D-X-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-, (SEQ ID NO: 11)
D-X-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-, (SEQ ID NO: 12)
D-X-L-K-A-F-Y-D-K-V-F-E-K-L-K-E-F-F-, (SEQ ID NO: 13)
D-X-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-F-F-, (SEQ ID NO: 14)
D-X-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-, (SEQ ID NO: 15)
E-X-L-K-L-F-Y-E-K-V-L-E-K-F-K-E-A-F-, (SEQ ID NO: 16)
E-X-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-, (SEQ ID NO: 17)
18
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
E-X-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-F-, (SEQ ID NO: 18)
E-X-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-, (SEQ ID NO: 19)
E-X-L-K-A-F-Y-D-K-V-F-E-K-L-K-E-F-F-, (SEQ ID NO: 20)
E-X-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-F-F-, (SEQ ID NO: 21)
E-X-L K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-, (SEQ ID NO: 22)
D-X-L-K-A-L-Y-D-K-V-A-E-K-L-K-E-A-L-, (SEQ ID NO: 23)
D-X-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-, (SEQ ID NO: 24)
D-X-F-K-A-F-Y-E-K-F-F-E-K-F-K-E-F-F-, (SEQ ID NO: 25)
E-X-L-K-A-L-Y-E-K-V-A-E-K-L-K-E-A-L-, (SEQ ID NO: 26)
E-X-L-K-A-F-Y-E-K-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 27)
E-X-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-, (SEQ ID NO: 28)
E-X-L-K-A-F-Y-E-K-V-F-E-K-F-K-E-F-F-, (SEQ ID NO: 29)
E-X-L-K-A-F-Y-E-K-F-F-E-K-F-K-E-F-F-, (SEQ ID NO: 30)
E-X-F-K-A-F-Y-E-K-F-F-E-K-F-K-E-F-F-, (SEQ ID NO: 31)
D-F-L-K-A-X-Y-D-K-V-A-E-K-L-K-E-A-X-, (SEQ ID NO: 32)
E-F-L-K-A X-Y-E-K-V-A-E-K-L-K-E-A-X-, (SEQ ID NO: 33)
D-F-X-K-A-X-Y-D-K-V-A-E-K-L-K-E-X-X-, (SEQ ID NO: 34)
E-F-X-K-A-X-Y-E-K-V-A-E-K-L-K-E-X-X-, (SEQ ID NO: 35)
D-K-L-K-A-F-Y-D-K-V-F-E-X-A-K-E-A-F-, (SEQ ID NO: 36)
D-K-X-K-A-V-Y-D-K-F-A-E-A-F-K-E-F-L-, (SEQ ID NO: 37)
E-K-L-K-A-F-Y-E-K-V-F-E-X-A-K-E-A-F-, (SEQ ID NO: 38)
E-K-X-K-A-V-Y-E-K-F-A-E-A-F-K-E-F-L-, (SEQ ID NO: 39)
D-X-L-K-A-F-V-D-K-F-A-E-K-F-K-E-A-Y-, (SEQ ID NO: 40)
E-K-X-K-A-V-Y-E-K-F-A-E-A-F-K-E-F-L-, (SEQ ID NO: 41)
D-X-L-K-A-F-V-Y-D-K-V-F-K-L-K-E-F-F-, (SEQ ID NO: 42)
E-X-L-K-A-F-V-Y-E-K-V-F-K-L-K-E-F-F-, (SEQ ID NO: 43)
D-X-L-R-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 44)
E-X-L-R-A-F-Y-E-K-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 45)
D-X-L-K-A-F-Y-D-R-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 46)
E-X-L-K-A-F-Y-E-R-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 47)
D-X-L-K-A-F-Y-D-K-V-A-E-R-L-K-E-A-F-, (SEQ ID NO: 48)
19
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
E-X-L-K-A-F-Y-E-K-V-A-E-R-L-K-E-A-F-, (SEQ ID NO: 49)
D-X-L-K-A-F-Y-D-K-V-A-E-K-L-R-E-A-F-, (SEQ ID NO: 50)
E-X-L-K-A-F-Y-E-K-V-A-E-K-L-R-E-A-F-, (SEQ ID NO: 51)
D-X-L-K-A-F-Y-D-R-V-A-E-R-L-K-E-A-F-, (SEQ ID NO: 52)
E-X-L-K-A-F-Y-E-R-V-A-E-R-L-K-E-A-F-, (SEQ ID NO: 53)
D-X-L-R-A-F-Y-D-K-V-A-E-K-L-R-E-A-F-, (SEQ ID NO: 54)
E-X-L-R-A-F-Y-E-K-V-A-E-K-L-R-E-A-F-, (SEQ ID NO: 55)
D-X-L-R-A-F-Y-D-R-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 56)
X-L-R-A-F-Y-E-R-V-A-E-K-L-K-E-A-F-, (SEQ ID NO: 57)
D-X-L-K-A-F-Y-D-K-V-A-E-R-L-R-E-A-F-, (SEQ ID NO: 58)
E-X-L-K-A-F-Y-E-K-V-A-E-R-L-R-E-A-F-, (SEQ ID NO: 59)
D-X-L-R-A-F-Y-D-K-V-A-E-R-L-K-E-A-F-, (SEQ ID NO: 60)
E-X-L-R-A-F-Y-E-K-V-A-E-R-L-K-E-A-F-, (SEQ ID NO: 61)
D-X-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-P-D-X-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F,
(SEQ ID NO: 62)
D-X-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-F-P-D-X-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-F,
(SEQ ID NO: 63)
D-X-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-P-D-X-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F,
(SEQ ID NO: 64)
D-K-L-K-A-F-Y-D-K-V-F-E-X-A-K-E-A-F-P-D-K-L-K-A-F-Y-D-K-V-F-E-X-L-K-E-A-F,
(SEQ ID NO: 65)
D-K-X-K-A-V-Y-D-K-F-A-E-A-F-K-E-F-L-P-D-K-X-K-A-V-Y-D-K-F-A-E-A-F-K-E-F-L,
(SEQ ID NO: 66)
D-X-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-P-D-X-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F,
(SEQ ID NO: 67)
D-X-L-K-A-F-V-Y-D-K-V-F-K-L-K-E-F-F-P-D-X-L-K-A-F-V-Y-D-K-V-F-K-L-K-E-F-F,
(SEQ ID NO: 68)
and D-X-L-K-A-F-Y-D-K-F-A-E-K-F-K-E-F-F-P-D-X-L-K-A-F-Y-D-K-F-A-E-K-F-K-E-F-F;
(SEQ ID NO: 69)
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
wherein X is a tryptophan or an oxidant resistant residue (e.g.,
phenylalanine) and at least one X
in each sequence is substituted for an oxidant resistant residue.
It will be appreciated that biologically functional equivalents, or even
improvements, of
the HDL, ApoAl, ApoAlmimetics can be made, generally using ApoAl as a starting
point.
Modifications and changes may be made in the structure of such a protein and
still obtain a
molecule having like or otherwise desirable characteristics. For example,
certain amino acids
may be substituted for other amino acids in the protein structure without
appreciable loss of
activity.
It is also well understood by the skilled artisan that, inherent in the
definition of a
"biologically functional equivalent or fragment" protein or polypeptide, is
the concept that there
is a limit to the number of changes that may be made within a defined portion
of the molecule
and still result in a molecule with an acceptable level of equivalent
biological activity.
Biologically functional equivalent proteins and peptides are thus defined
herein as those proteins
and peptides in which certain, not most or all, of the amino acids may be
substituted. Of course, a
plurality of distinct proteins/peptides with different substitutions may
easily be made and used in
accordance with the invention.
Amino acid substitutions are generally based on the relative similarity of the
amino acid
side-chain substituents, for example, their hydrophobicity, hydrophilicity,
charge, size, and the
like. An analysis of the size, shape and type of amino acid side-chain
substituents reveals that
arginine, lysine, and histidine are all positively charged residues; that
alanine, glycine and serine
are all a similar size. Therefore, based upon these considerations, arginine,
lysine and histidine;
alanine, glycine and serine are defined herein as biologically functional
equivalents.
Following the procedures noted in the published application by Alton et at.
(W083/04053), one
can readily design and manufacture genes coding for microbial expression of
polypeptides
having primary conformations which differ from that herein specified in terms
of the identity or
location of one or more residues (e.g. substitutions, terminal and
intermediate additions and
deletions). Alternately, modifications of cDNA and genomic genes may be
readily accomplished
by well-known site-directed mutagenesis techniques and employed to generate
analogs and
derivatives of ApoAl. Such products would share at least one of the biological
properties of
ApoAl but may differ in others.
21
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
Fragments of ApoAl or fragments of ApoAl mimetic that are biologically active
with
respect to treating cancer can be identified by one of skill in the art. For
example a given
fragment or mimetic (or mimetic fragment) of ApoAl can be substituted for the
ApoAl in the
Examples below. In this regard, these Examples can be re-run to determine if
the fragment or
mimetic has the same or better biological activity as ApoAl as it relates to
successfully treating
cancer. Other assays, besides those detailed in the Examples, can also be run
using the enormous
number of cancer compound screening assays known in the art. For example, a
candidate
fragment of ApoAl or mimetic can simply be substituted for the test cancer
compound in these
prior art assays, found, for example, in both journal articles and patents.
One could, for example,
do a search in PubMed or the Patent databases for "cancer screening assay" and
then employ one
or more of the assays found in these publications or patents.
The HDL, ApoAl, and/or ApoAl mimetics of the present invention may be purified
and
isolated. The term "purified and isolated" herein means substantially free of
unwanted
substances so that the present lipoproteins can be used to treat cancer. For
example, one may
have a modified recombinant human ApoAl mimetic polypeptide substantially free
of other
human proteins or pathological agents. These polypeptides are also
characterized by being a
product of mammalian cells, or the product of chemical synthetic procedures or
of prokaryotic or
eukaryotic host expression (e.g., by bacterial, yeast, higher plant, insect
and mammalian cells in
culture) of exogenous DNA sequences obtained by genomic or cDNA cloning or by
gene
synthesis. The products of expression in typical yeast (e.g., Saccharomyces
cerevisiae) or
prokaryote (e.g., E. coli) host cells are free of association with any
mammalian proteins. The
products of expression in vertebrate (e.g., non-human mammalian (e.g., COS or
CHO) and
avian) cells are free of association with any human proteins. Depending upon
the host employed,
and other factors, polypeptides of the invention may be glycosylated with
mammalian or other
eucaryotic carbohydrates or may be non-glycosylated. Polypeptides of the
invention may also
include an initial methionine amino acid residue (at position-1 with respect
to the first amino
acid residue of the polypeptide).
The lipoproteins and peptides of the invention can be purified by art-known
techniques
such as reverse phase chromatography high performance liquid chromatography,
ion exchange
chromatography, gel electrophoresis, affinity chromatography and the like. The
actual conditions
used to purify a particular peptide will depend, in part, on the synthesis
strategy and on factors,
22
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
such as net charge, hydrophobicity, hydrophilicity, etc., and will be apparent
to those having skill
in the art. Multimeric branched peptides can be purified, e.g., by ion
exchange or size exclusion
chromatography.
For affinity chromatography purification, any antibody which specifically
binds the
peptide may be used. For the production of antibodies, various host animals,
including but not
limited to rabbits, mice, rats, etc., may be immunized by injection with a
peptide. The peptide
may be attached to a suitable carrier, such as BSA, by means of a side chain
functional group or
linkers attached to a side chain functional group. Various adjuvants may be
used to increase the
immunological response, depending on the host species, including but not
limited to Freund's
(complete and incomplete), mineral gels such as aluminum hydroxide, surface
active substances
such as hemocyanin, dinitrophenol, and potentially useful human adjuvants such
as BCG (bacilli
Calmette-Guerin) and Corynebacterium parvum.
Cancers and related disorders that can be prevented, treated, or managed by
methods and
compositions of the present invention include but are not limited to the
following cancers:
leukemias, such as but not limited to, acute leukemia, acute myeloid leukemia
(AML), chronic
myelogenous (or myeloid) leukemia (CML), acute lymphocytic leukemia, acute
myelocytic
leukemias, such as, myeloblastic, promyelocytic, myclomonocytic, monocytic,
and
erythroleukemia leukemias and myelodysplastic syndrome; chronic leukemias,
such as but not
limited to, chronic myelocytic (granulocytic) leukemia, chronic lympocytic
leukemia, hairy cell
leukemia, polycythemia vera; lymphomas such as but not limited to Hodgkin's
disease, non-
Hodgkin's disease; multiple myelomas such as but not limited to smoldering
multiple myeloma,
nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary
plasmacytoma
and extramedullary plasmacytoma=, Waldenstrom's macroglobulinemia; monoclonal
gammopathy of undetermined significance; benign monoclonal gammopathy; heavy
chain
disease; bone and connective tissue sarcomas such as but not limited to bone
sarcoma,
osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor,
fibrosarcoma of
bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma
(hemangiosarcoma),
fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma,
lymphangiosarcoma,
neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumors such as but not
limited to,
glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma,
nonglial tumor,
acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma,
pineocytoma,
23
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
pineoblastoma, primary brain lymphoma; breast cancer including but not limited
to ductal
carcinoma, adenocarcinoma, lobular (small cell) carcinoma, intraductal
carcinoma, medullary
breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast
cancer, Paget's
disease, and inflammatory breast cancer; adrenal cancer such as but not
limited to
pheochrmocytom and adrenocortical carcinoma; thyroid cancer such as but not
limited to
papillary or follicular thyroid cancer, medullary thyroid cancer and
anaplastic thyroid cancer;
pancreatic cancer such as but not limited to, insulinoma, gastrinoma,
glucagonoma, vipoma,
somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary
cancers such as but not
limited to Cushing's disease, prolactin-secreting tumor, acromegaly, and
diabetes insipius; eye
cancers such as but not limited to ocular melanoma such as iris melanoma,
choroidal melanoma,
and cilliary body melanoma, and retinoblastoma; vaginal cancers such as
squamous cell
carcinoma, adenocarcinoma, and melanoma; vulvar cancer such as squamous cell
carcinoma,
melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease;
cervical cancers
such as but not limited to squamous cell carcinoma, and adenocarcinoma;
uterine cancers such as
but not limited to endometrial carcinoma, borderline tumor, germ cell tumor,
and stromal tumor;
esophageal cancers such as but not limited to, squamous cancer,
adenocarcinoma, adenoid cystic
carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma,
melanoma,
plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma;
stomach cancers such
as but not limited to, adenocarcinoma, fungating (polypoid), ulcerating,
superficial spreading,
diffusely spreading, malignant lymphoma, fibrosarcoma, and carcinosarcoma;
colon cancers;
rectal cancers; liver cancers such as but not limited to hepatocellular
carcinoma and
hepatoblastoma; gallbladder cancers such as adenocarcinoma;
cholangiocarcionomas such as but
not limited to pappilary, nodular, and diffuse; lung cancers such as non-small
cell lung cancer,
squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell
carcinoma, and
small-cell lung cancer; testicular cancers such as but not limited to germinal
tumor, seminoma,
anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal
carcinoma, teratoma
carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers such as but not
limited to,
prostatic intraepithelial neoplasia, adenocarcinoma, leiomyosarcoma, and
rhabdomyosarcoma;
penal cancers; oral cancers such as but not limited to squamous cell
carcinoma; basal cancers;
salivary gland cancers such as but not limited to adenocarcinoma,
mucoepidermoid carcinoma,
and adenocystic carcinoma; pharynx cancers such as but not limited to squamous
cell cancer, and
24
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
verrucous; skin cancers such as but not limited to basal cell carcinoma,
squamous cell carcinoma
and melanoma, superficial spreading melanoma, nodular melanoma, lentigo
malignant
melanoma, acral lentiginous melanoma; kidney cancers such as but not limited
to renal cell
carcinoma, adenocarcinoma, hypemephroma, fibrosarcoma, transitional cell
cancer (renal pelvis
and/or uterer); Wilms' tumor; bladder cancers such as but not limited to
transitional cell
carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition,
cancers include
myxsarcoma, osteogenic sarcoma, endotheliosarcoma,
lymphangioendotheliosarcoma,
mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma,
cystadenocarcinoma,
bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma,
papillary
carcinoma and papillary adenocarcinomas (for review of such disorders, see
Fishman et al.,
1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al.,
1997, Informed
Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery,
Viking Penguin,
Penguin Books U.S.A., Inc., United States of America)
Accordingly, the compositions and methods of the invention are useful in the
treatment or
prevention of a variety of cancers or other abnormal proliferative diseases,
including (but not
limited to) the following: carcinoma, including that of the bladder, breast,
prostate, rectal, colon,
kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin;
including squamous cell
carcinoma; hematopoictic tumors of myeloid lineage, including acute and
chronic myelogenous
leukemias and promoclocytic leukemia; tumors of mesenchymal origin; including
fibrosarcoma
and rhabdomyoscarcoma; other tumors, including melanoma, seminoma,
tetratocarcinoma,
neuroblastoma, and glioma; tumors of the central and peripheral nervous
system, including
astrocytoma, neuroblastoma, glioma, and schwannomas; tumors of mesenchymal
origin,
including fibrosarcoma, rhabdomyoscarama, and osteosarcoma; and other tumors,
including
melanoma, xeroderma pigmentosum, keratoactanthoma, seminoma, thyroid
follicular cancer and
teratocarcinoma. It is also contemplated that cancers caused by aberrations in
apoptosis would
also be treated by the methods and compositions of the invention. Such cancers
may include but
not be limited to follicular lymphomas, hormone dependent tumors of the
breast, prostate and
ovary, and precancerous lesions such as familial adenomatous polyposis, and
myelodysplastic
syndromes. In specific embodiments, malignancy or dysproliferative changes
(such as metaplasis
and dyplasias), or hyperproliferative disorders, are treated in the skin,
lung, colon, rectum, breast,
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
prostate, bladder, kidney, pancreas, ovary, or uterus. In other specific
embodiments, sarcoma,
melanoma, small lung carcinoma, or leukemia is treated.
In some embodiments, the cancer is malignant. In other embodiments, the
disorder to be
treated is a pre-cancerous condition. In a specific embodiment, the pre-
cancerous condition is
high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the
breast, or fibrocystic
disease.
In certain embodiments, the compositions of the invention can be delivered to
cancer
cells by site-specific means. Cell-type specific delivery can be provided by
conjugating a
therapeutic agent to a targeting molecule, for example, one that selectively
binds to the affected
cells. Methods for targeting include conjugates, such as those described in
U.S. Patent No.
5,391,723. Targeting vehicles, such as liposomes, can be used to deliver a
compound, for
example, by encapsulating the compound in a liposome containing a cell-
specific targeting
molecule. Methods for targeted delivery of compounds to particular cell types
are well-known to
those skilled in the art.
In certain embodiments, compositions of the present invention can be
administered
together (simultaneously) or at different times (sequentially). In addition,
therapy by
administration of one or more HDL, ApoAl, and/or ApoAl mimetics (or other
compositions of
the present invention) can be combined with the administration of one or more
therapies such as,
but not limited to, chemotherapies, radiation therapies, hormonal therapies,
and/or biological
therapies/immunotherapies. Prophylactic/therapeutic agents include but are not
limited to,
proteinaceous molecules, including, but not limited to, peptides,
polypeptides, proteins, including
post-translationally modified proteins, antibodies, etc.; or small molecules
(less than 1000
daltons), inorganic or organic compounds; or nucleic acid molecules, including
but not limited
to, double-stranded or single-stranded DNA, or double-stranded or single-
stranded RNA, as well
as triple helix nucleic acid molecules. Prophylactic/therapeutic agents can be
derived from any
known organism (including, but not limited to, animals, plants, bacteria,
fungi, and protista, or
viruses) or from a library of synthetic molecules.
The present invention also encompasses the use of HDL, ApoAl, and/or ApoAl
mimetics (and other compositions of the present invention) for the manufacture
of a medicament
for the treatment of cancers, such as malignant melanoma, lung, breast, colon,
kidney, bladder,
prostate, pancreatic, oral, head and neck, sarcomas, lymphomas (B-cell and T-
cell) and adrenal
26
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
cancer or tumors or other cancers or tumor metastases. The present invention
also encompasses
a pharmaceutical composition that includes HDL, ApoAl, and/or ApoAl mimetics
in
combination with a pharmaceutically acceptable carrier.
The pharmaceutical composition can include a pharmaceutically acceptable
carrier and a
non-toxic therapeutically effective amount of HDL, ApoAl, and/or ApoAl
mimetics, or other
compositions of the present invention.
Moreover, the invention encompasses a pharmaceutical composition for the
treatment of
disease, the use of which results in the inhibition of growth of neoplastic
cells, benign or
malignant tumors, or metastases, comprising a pharmaceutically acceptable
carrier and a non-
toxic therapeutically effective amount of HDL, ApoAl, and/or ApoAl mimetics,
or other
compositions of the present invention.
The phrases "pharmaceutically or pharmacologically acceptable" refer to
molecular
entities and compositions that do not produce an adverse, allergic, or other
untoward reaction
when administered to an animal, or a human, as appropriate. Veterinary uses
are equally
included within the invention and "pharmaceutically acceptable" formulations
include
formulations for both clinical and/or veterinary use.
As used herein, "pharmaceutically acceptable carrier" includes any and all
solvents,
dispersion media, coatings, antibacterial, and antifungal agents, isotonic and
absorption delaying
agents and the like. The use of such media and agents for pharmaceutical
active substances is
well known in the art. Except insofar as any conventional media or agent is
incompatible with
the active ingredient, its use in the therapeutic compositions is
contemplated. For human
administration, preparations should meet sterility, pyrogenicity, general
safety and purity
standards as required by FDA Office of Biologics standards. Supplementary
active ingredients
can also be incorporated into the compositions.
Examples of carriers include solvents and dispersion media containing, for
example,
water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol,
and the like), mixtures thereof, and vegetable oils. In many cases, it will be
preferable to include
isotonic agents, for example, by the use of a coating, such as lecithin, by
the maintenance of the
required particle size in the case of dispersion and/or by the use of
surfactants.
The present invention contemplates the administration of the described
pharmaceutical
compositions by various routes. Pharmaceutical compositions comprising HDL,
ApoAl, and/or
27
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
ApoAl mimetics of the invention may be administered by any route that ensures
bioavailability
in the circulation. These routes can include, but are by no means limited to
parenteral
administration, systemic administration, oral administration, nasal
administration, rectal
administration, intraperitoneal injection, intravascular injection,
subcutaneous injection,
transcutaneous administration, inhalation administration, and intramuscular
injection.
Injectable preparations include sterile suspensions, solutions or emulsions of
the active
ingredient in aqueous or oily vehicles. The compositions may also contain
formulating agents,
such as suspending, stabilizing and/or dispersing agent. The formulations for
injection may be
presented in unit dosage form, e.g. in ampoules or in multidose containers,
and may contain
added preservatives.
Alternatively, the injectable formulation may be provided in powder form for
reconstitution with a vehicle, including but not limited to sterile pyrogen
free water, buffer,
dextrose solution, etc., before use. To this end HDL, ApoAl, and/or ApoAl
mimetics of the
present invention may be lyophilized, or the co-lyophilized peptide-lipid
complex may be
prepared. The stored preparations can be supplied in unit dosage forms and
reconstituted prior to
use in vivo.
For prolonged delivery, the active ingredient can be formulated as a depot
preparation,
for administration by implantation; e.g., subcutaneous, intradermal, or
intramuscular injection.
Thus, for example, the active ingredient may be formulated with polymeric or
hydrophobic
materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins,
or as sparingly
soluble derivatives; e.g., as a sparingly soluble salt form of the modified
HDL, ApoAl, and/or
ApoAl mimetics.
Alternatively, transdermal delivery systems manufactured as an adhesive disc
or patch
which slowly releases the active ingredient for percutaneous absorption may be
used. To this
end, permeation enhancers may be used to facilitate transdermal penetration of
the active
ingredient.
For oral administration, the pharmaceutical compositions may take the form of,
for
example, tablets or capsules prepared by conventional means with
pharmaceutically acceptable
excipients, such as binding agents (e.g., pregelatinised maize starch,
polyvinylpryrrolidone or
hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline
cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica);
disintegrants (e.g.,
28
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
potato starch or sodium starch glycolate); or wetting agents (e.g., sodium
lauryl sulfate). The
tablets may be coated by methods well known in the art. Liquid preparations
for oral
administration may take the form of, for example, solutions, syrups or
suspensions, or they may
be presented as a dry product for constitution with water or other suitable
vehicle before use.
Such liquid preparations may be prepared by conventional means with
pharmaceutically
acceptable additives, such as suspending agents (e.g., sorbitol syrup,
cellulose derivatives or
hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-
aqueous vehicles
(e.g., almond oil, oily ester, ethyl alcohol or fractioned vegetable oils):
and preservatives (e.g.,
methyl or propyl-p-hydroxybenzoates or ascorbic acid). The preparations may
also contain
buffer salts, flavoring, coloring, and sweetening agents as appropriate.
Preparations for oral
administration may be suitably formulated to give controlled release of the
active compound.
For buccal administration, the compositions may take the form of tablets or
lozenges
formulated in conventional manner. For rectal and vaginal routes of
administration, the active
ingredient may be formulated as solutions (for retention enemas) suppositories
or ointments.
For administration by inhalation, the active ingredient can be conveniently
delivered in
the form of an aerosol spray presentation from pressurized packs or a
nebulizer, with the use of a
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane,
carbon dioxide or other gas. In the case of a pressurized aerosol, the dosage
unit may be
determined by providing a valve to deliver a metered amount. Capsules and
cartridges of e.g.
gelatin for use in an inhaler or insufflators may be formulated containing a
powder mix of the
compound and a suitable powder base such as lactose or starch.
The compositions may, if desired, be presented in a pack or dispenser device,
which may
contain one or more unit of dosage forms containing the active ingredient. The
pack may for
example comprise metal or plastic foil, such as a blister pack. The pack or
dispenser device may
be accompanied by instructions for administration.
"Unit dosage" formulations are those containing a dose or sub-dose of the
administered
ingredient adapted for a particular timed delivery. For example, exemplary
"unit dosage"
formulations are those containing a daily dose or unit or daily sub-dose or a
weekly dose or unit
or weekly sub-dose and the like.
Under ordinary conditions of storage and use, all such preparations should
contain a
preservative to prevent the growth of microorganisms. The prevention of the
action of
29
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
microorganisms can be brought about by various antibacterial and antifungal
agents, for
example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the
like. Prolonged
absorption of the injectable compositions can be brought about by the use in
the compositions of
agents delaying absorption, for example, aluminum monostearate and gelatin.
Prior to or upon formulation, HDL, ApoAl, and/or ApoAl mimetics should be
extensively dialyzed to remove undesired small molecular weight molecules,
and/or lyophilized
for more ready formulation into a desired vehicle, where appropriate. Sterile
injectable solutions
are prepared by incorporating the active ingredients in the required amount in
the appropriate
solvent with various of the other ingredients enumerated above, as desired,
followed by filtered
sterilization. Generally, dispersions are prepared by incorporating the
various sterilized active
ingredients into a sterile vehicle that contains the basic dispersion medium
and the required other
ingredients from those enumerated above.
In the case of sterile powders for the preparation of sterile injectable
solutions, the
preferred methods of preparation are vacuum-drying and freeze-drying
techniques that yield a
powder of the active ingredient, plus any additional desired ingredient from a
previously sterile-
filtered solution thereof.
Pharmaceutical "slow release" capsules or "sustained release" compositions or
preparations may be used and are generally applicable. Slow release
formulations are generally
designed to give a constant drug level over an extended period and may be used
to deliver
ApoAl mimetic polypeptides or fragments thereof in accordance with the present
invention.
In certain embodiments, liposomes and/or nanoparticles may also be employed
with the HDL,
ApoAl, and/or ApoAl mimetics. The formation and use of liposomes is generally
known to
those of skill in the art, as summarized below. Liposomes are formed from
phospholipids that are
dispersed in an aqueous medium and spontaneously form multilamellar concentric
bilayer
vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have
diameters of from 25
nm to 4 gm. Sonication of MLVs results in the formation of small unilamellar
vesicles (SUVs)
with diameters in the range of 200 to 500 A, containing an aqueous solution in
the core. HDL,
ApoAl, and/or ApoAl mimetics can also formulated be into phospholipid discs of
between 8
and 20 nm, through spontaneous reaction with phospholipid liposomes, or
through the cholate
dialysis procedure.
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
Nanocapsules can generally entrap compounds in a stable and reproducible way.
To
avoid side effects due to intracellular polymeric overloading, such ultrafine
particles (sized
around 0.1 gm) should be designed using polymers able to be degraded in vivo.
Biodegradable
polyalkyl-cyanoacrylate nanoparticles that meet these requirements are
contemplated for use in
the present invention, and such particles may be are easily made.
In a further aspect of the invention, HDL, ApoAl, and/or ApoAl mimetics can be
used in
combination and adjunctive therapies for inhibiting cancer cell proliferation
and growth. The
phrase "combination therapy" embraces the administration of HDL, ApoAl, and/or
ApoAl
mimetics and an additional therapeutic agent as part of a specific treatment
regimen intended to
provide a beneficial effect from the co-action of these therapeutic agents.
Administration of these
therapeutic agents in combination typically is carried out over a defined time
period (usually
minutes, hours, days or weeks depending upon the combination selected). The
phrase
"adjunctive therapy" encompasses treatment of a subject with agents that
reduce or avoid side
effects associated with the combination therapy of the present invention.
A combination therapy is intended to embrace administration of these
therapeutic agents
in a sequential manner, that is, wherein each therapeutic agent is
administered at a different time,
as well as administration of these therapeutic agents, or at least two of the
therapeutic agents, in a
substantially simultaneous manner. Substantially simultaneous administration
can be
accomplished, for example, by administering to the subject a single capsule
having a fixed ratio
of each therapeutic agent or in multiple, single capsules for each of the
therapeutic agents.
Sequential or substantially simultaneous administration of each therapeutic
agent can be effected
by an appropriate route including, but not limited to, oral routes,
intravenous routes,
intramuscular routes, and direct absorption through mucous membrane tissues.
There therapeutic
agents can be administered by the same route or by different routes. The
sequence in which the
therapeutic agents are administered is not narrowly critical.
Combination therapy also can embrace the administration of the therapeutic
agents as
described above in further combination with other biologically active
ingredients (such as, but
not limited to, a second and different therapeutic agent) and non-drug
therapies (such as, but not
limited to, surgery or radiation treatment). Where the combination therapy
further comprises
radiation treatment, the radiation treatment may be conducted at any suitable
time so long as a
beneficial effect from the co-action of the combination of the therapeutic
agents and radiation
31
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
treatment is achieved. For example, in appropriate cases, the beneficial
effect is still achieved
when the radiation treatment is temporarily removed from the administration of
the therapeutic
agents, perhaps by days or even weeks.
In certain embodiments, HDL, ApoAl, and/or ApoAl mimetics can be administered
in
combination with at least one anti-proliferative agent selected from the group
consisting of
chemotherapeutic agent, an antimetabolite, and antitumorgenic agent, and
antimitotic agent, and
antiviral agent, and antineoplastic agent, an immunotherapeutic agent, and a
radiotherapeutic
agent.
The phrase "anti-proliferative agent" can included agents that exert
antineoplastic,
chemotherapeutic, antiviral, antimitotic, antitumorgenic, and/or
immunotherapeutic effects, e.g.,
prevent the development, maturation, or spread of neoplastic cells, directly
on the tumor cell,
e.g., by cytostatic or cytocidal effects, and not indirectly through
mechanisms such as biological
response modification. There are large numbers of anti-proliferative agent
agents available in
commercial use, in clinical evaluation and in pre-clinical development, which
could be included
in the present invention by combination drug chemotherapy. For convenience of
discussion, anti-
proliferative agents are classified into the following classes, subtypes and
species: ACE
inhibitors, alkylating agents, angiogenesis inhibitors, angiostatin,
anthracyclines/DNA
intercalators, anti-cancer antibiotics or antibiotic-type agents,
antimetabolites, antimetastatic
compounds, asparaginases, bisphosphonates, cGMP phosphodiesterase inhibitors,
calcium
carbonate, cyclooxygenase-2 inhibitors, DHA derivatives, DNA topoisomerase,
endostatin,
epipodophylotoxins, genistein, hormonal anticancer agents, hydrophilic bile
acids (URSO),
immunomodulators or immunological agents, integrin antagonists, interferon
antagonists or
agents, MMP inhibitors, miscellaneous antineoplastic agents, monoclonal
antibodies,
nitrosoureas, NSAIDs, ornithine decarboxylase inhibitors, pBATTs, radio/chemo
sensitizers/protectors, retinoids, selective inhibitors of proliferation and
migration of endothelia
cells, selenium, stromelysin inhibitors, taxanes, vaccines, and vinca
alkaloids.
The major categories that some anti-proliferative agents fall into include
antimetabolite agents,
alkylating agents, antibiotic-type agents, hormonal anticancer agents,
immunological agents,
interferon-type agents, and a category of miscellaneous antineoplastic agents.
Some anti-
proliferative agents operate through multiple or unknown mechanisms and can
thus be classified
into more than one category.
32
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
Another aspect of the present invention relates to a method of treating cancer
in a subject
by administering to the subject at least one agent that stimulates the
cellular receptors for HDL,
the SR-B1 receptor, and/or the cellular cholesterol transporters ABCA1 and
ABCG1. The agent
can comprise at least one of small molecules, peptide mimetics, antibodies or
fragments thereof
and be administered to the subject to protect the subject against a wide
variety of cancers
including but not limited to malignant melanoma, lung, breast, colon, brain,
kidney, bladder,
prostate, pancreatic, oral, head and neck, sarcomas, lymphomas (B-cell and T-
cell) and adrenal
cancer development as well as slow development of tumors, slow tumor
metastasis , and
lengthen survival time of the subject.
A further aspect of the invention relates to a diagnostic method for
characterizing a
subject's risk for cancer. The diagnostic method can included determining the
level of
dysfunctional HDL in a subject and comparing the measured level to a control
value. An increase
in the measured level of dysfunctional HDL compared to the control value can
correlate with
lack of protection against a wide variety of cancers including, malignant
melanoma, lung, breast,
colon, brain, kidney, bladder, prostate, pancreatic, oral, head and neck,
sarcomas, lymphomas
(B-cell and T-cell) and adrenal cancer development; facilitate development of
tumors, tumor
metastasis and shorten survival times.
The following examples are included to demonstrate preferred embodiments of
the
invention. It should be appreciated by those of skill in the art that the
techniques disclosed in the
examples which follow represent techniques discovered by the inventor to
function well in the
practice of the invention, and thus can be considered to constitute preferred
modes for its
practice. However, those of skill in the art should, in light of the present
disclosure, appreciate
that many changes can be made in the specific embodiments which are disclosed
and still obtain
a like or similar result without departing from the spirit and scope of the
invention.
30
33
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
EXAMPLES
EXAMPLE 1
ApoAl and DHDL acts to retard cancer growth, development and metastasis and
activates
a subset of innate immune hose defense genes and decreases a subset of
cellular
proliferation genes and genes associated with cancer.
HDL isolated from human plasma was used initially to treat bone marrow-derived
macrophages grown in culture from wild type (WT) C57/BL6 mice at various
concentrations
ranging from non to high physiological levels (750 microgram protein/ml).
Cells were harvested
after 8 hour exposure to HDL and total RNA prepared and used for gene chip
analysis. HDL
exposure resulted in increased expression of a number of genes associated with
innate immune
functions in addition to those associated with cholesterol metabolism. Genes
that were down-
regulated by HDL exposure included a subset of genes associated with cellular
proliferation and
genes associated with cancer progression and metastasis. These finding led to
the hypothesis
that HDL and perhaps ApoAl its major protein constituent may play an important
role in
protection from cancer or tumorogenesis.
To test this hypothesis, the behavior of a metastatic murine melanoma cell
line,
B16F1OL, was examined after inoculating 100,000 cells per site on the left and
right dorsal flank
of ApoAl deficient, wild type or human ApoAl expressing transgenic mice. Figs.
1-3 show that
ApoAl deficient mice (ApoAl-/-) are more susceptible to malignant melanoma
development,
tumor burden and survival time than wild type C57/BL6 (WT) mice littermate
mice or to human
ApoAl expressing transgenic (ApoAl-Tg)/C57/BL6 mice. The ApoAl-Tg mice are
more
protected from malignant melanoma development, tumor burden and have a longer
survival time
than the WT mice. Total tumor burden is lowest in ApoAl transgenic animals as
was metastasis
as determined by ventral side imaging of tumors. ApoAl is the major protein
component of high
density lipoprotein (HDL). HDL plasma levels were highest in the ApoAl -Tg
mice followed by
the WT mice and the ApoAl deficient mice were devoid of HDL as measured.
It was hypothesized that ApoAl is a key regulator of this anti-cancer
protective response.
Peptide mimetics of HDL have been reported and those peptides enhance the anti-
inflammatory
function of HDL and promote enhanced cholesterol efflux in vivo. It is
anticipated that these
mimetics and others that provide enhanced HDL function will also prove to have
an anti-cancer
34
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
protective response. It also follows that oxidant resistant forms of apoAl
that can be
reconstituted into nascent HDL and shown to provide enhanced HDL function
under conditions
that result in oxidatively damaged HDL (and loss of anti-inflammatory, and
cholesterol efflux
activity) will provide even greater protection than wild type apoAl when
infused.
There are a number of different oxidant resistant forms of apoAl that include
residues
that when mutated from tryptophan's to phenylalanines provide protection from
loss of
cholesterol efflux activity 4WF Apoal and 72F ApoAl. Tyrosine 166 mutated to
glutamic acid
(E) or aspartic acid (D) protects nascent HDLs reconstituted with this version
of ApoAl to
interact and stimulate Lecithin-cholesterol acyltransferase (LCAT) binding and
are capable of
stimulating LCAT activity. Another oxidant resistant form of ApoAl will have
residues
different from those described above that when mutated fail to activate a
proinflammatory
cellular reaction including activation of nuclear factor kappa B transcription
factor, or vascular
cell adhesion molecule (VCAM) expression. Combinations of all of these various
mutants alone
and in combination with each other and the resulting ApoAl expressed from them
is expected to
provide an enhanced anti-cancer protective response when used alone or in
various phospholipid
mixtures or in various phospholipid/cholesterol reconstituted nascent HDL
particles.
It is also possible that once the most potent version of ApoAl has been
identified that has
anti-cancer protective properties it could be used, for example, in in vivo
gene therapy by
targeting the mutant allele for expression in the tumor vasculature using
peptide display along
with cell-type specific promoters to drive ApoAl expression primarily in the
tumor vasculature.
HDL when oxidized becomes dysfunctional and loses its anti-inflammatory
properties
and also its ability to promote cholesterol efflux and to bind its receptor
scavenger receptor B 1
(SR-B 1) and the cellular cholesterol transporters ABCA1 and ABCG1.
Athelerosclerotic
appearing vasculature has been noted in the tumor beds of a number of cancers
cited in the
literature. It is anticipated that increased levels of dysfunctional HDL
negatively impact HDL's
ability to provide protection from cancer. Accurate measurement of levels of
dysfunctional HDL
should give a predictive measurement of how well an individual is protected by
identifying the
true levels of protective HDL.
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
EXAMPLE 2
HDL exposure to macrophages induces gene expression from innate immune
function
genes and down regulates expression of cellular proliferation genes and genes
associated
with cancer progression and metastasis.
Bone marrow-derived macrophages from wild type female C57B1/6 mice (10-11 wks
old) were treated with increasing concentration of reconstituted HDL (up to
750 mg/ml) made
with human plasma-purified ApoAl). Total RNA was isolated after 7 hours
treatment and
processed for gene chip microarray studies using Illumina's mouse Ref-8 vl.1
beadchip.
Expression intensities were normalized and background corrected using
Beadstudio software. A
2-fold difference in expression with respect to control (PBS) treatment and a
detection p-value
<0.01 was taken as being significant.
Using the aforementioned criteria from two independent experiments, 99 and 269
genes
were found that were up and down regulated by HDL, respectively. Gene chip
data was
validated by TaqMan real time RT PCR on a whole panel of genes in these
studies. As
illustrated schematically in Figs. 4 and 5, ingenuity bioinformatics software
was used to examine
the biological pathways enriched by the genes regulated by HDL in these
experiments. Some of
the up regulated genes (28 of 99) mapped primarily to lipid biological
processes that included
cholesterol biosynthesis and transport. Significantly, 10 up-regulated genes
have anti-
proliferative function. (Fig. 4) The top biological function for down-
regulated genes was the cell
cycle, with the regulated genes having primarily pro-proliferation activities.
(Fig. 5)
Additionally, genes that positively regulate tumor development, tumor
metastasis and immune
cell trafficking were amongst those down-regulated by HDL.
EXAMPLE 3
ApoAl Inhibits Tumor Formation
In this the first part of this Example, Tg mice that were injected with F I
OL_B 16
melanoma tumors were given gene therapy with a vector expressing apoAl. It was
found that
gene therapy with apoAl is protective for cancer development (tumor growth and
metastases
formation). ApoAl transgenic mice show reduced tumor burden (Figure 6A),
growth rate
(Figure 6A), and metastases (Figure 6B) formation relative to wild type (WT)
mice. Al KO
(apoAl knock out) mice were also injected with F1OLB16 melanoma cells and
tumor
36
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
development was monitored. The results indicated that genetic deletion of
apoAl (apoAl-KO
mice) are more susceptible to development of tumor (Figure 6A), growth rate of
tumor (Figure
6A), and metastases formation (Figure 6B). In this Example, abbreviations are
as follows: KO=
ApoAl null on C57B1/6 background, tg= human ApoAl expressing transgenic
C57B1/6, Wt=
wild type C57B1/6.
In another part of this Example, KO and Tg or Tg/Tg mice were injected with
Lewis lung
cancer cells and monitored for tumor formation. Figure 7A shows the mean tumor
volume in the
mice after 48 days, and Figure 7B shows the survival percentage over time. The
Tg mice had
smaller tumor sizes and lived longer than the KO mice, showing the protective
effect of ApoAl.
In another part of this Example, Tg, WT, and A1KO mice were injected with F1OL
B16
melanoma tumor cells and monitored for survival. The results are shown in
Figure 8.
In another part of this Example, apoAl was injected subcutaneously into mice
every
other day and the plasma levels of apoAl at steady state (shown in Figure 9
for says 22-24) were
monitored. Figure 9 shows that the plasma level of apoAl is between 75-175
mg/dL. This
approximates the plasma levels of apoAl in humans.
In another part of this Example, human ApoAl or normal saline (control) was
given to
apoAl-KO mice throughout duration of the study following the dosing schedule
of 15 mg s.c.
QOD. 105 F1OL_B16 Melanoma Tumor cells were injected subcutaneously into the
dorsum of
the mice. Total tumor burden and metastases were quantified by xenogen
imaging. The results
for total tumor burden are shown in Figure 1 OA and the results for metastases
are shown in
Figure lOB. This data shows that giving apoAl to mice blocks tumor growth and
metastases
formation. Images of the mice 16 days post tumor injection are shown in Figure
11, which show
much greater tumor growth in the saline treated mice. Images of the mice 21
days post tumor
injection are shown in Figure 12, which show much greater tumor growth in the
saline treated
mice. A comparison by gender of the mice from Figure 12 is shown in Figure 13.
The survival
for these mice was also monitored and the results are shown in Figure 14,
which shows that the
ApoAl treated mice had much greater survival.
In another part of this Example, the impact of giving apoAl as a therapy is
evaluated
after the tumor growth is established and metastases are detectable. The same
malignant
melanoma animal model is employed. ApoAl injections were started one week
after tumor
injection. Overall tumor growth (Fig. 15a), and metastases formation (Fig.
15B), are
37
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
dramatically reduced in the animals that receive apoAl. In the insets for both
16A and 16B, note
that apoAl injections actually shrink peak tumor volume by -50% within 1-2
weeks of therapy.
A similar -50% reduction in peak metastases burden is also noted in the apoAl
treated mice.
These results indicate that apoAl treatment in established cancer can not only
halt progression of
tumor and metastases growth, but can actually reduce the extent of tumor
burden, and shrink
metastases.
In similar experiments, ApoA2 was given in the same dosing strategy as apoAl
vs
normal saline (S) control. As shown in Figure 16, ApoAl is markedly more
potent at reducing
cancer growth (Fig. 16A) and metastases formation (Fig. 16B).
In another part of this Example, spleen macrophages from B16_F1 OL tumor-
bearing
A1KO mice and A1Tg mice were compared. Spleen macrophages were quantified by
flow
cytometry as F4/80+ positive cells. The results are shown in Figure 17,
including cell number
(Fig. 17A) and F480+ cells as a percentage of splenocytes (Fig. 17B.). While
the present
invention is not limited to any particular mechanism and an understanding of
the mechanism is
not necessary to practice the invention, these results suggest that one
mechanism that apoAl
helps to reduce cancer development is through immunomodulatory effects on
innate immune
cells. This data shows that apoAl treatment lowers tumor associated macrophage
numbers.
In another part of this Example, myeloid derived suppressor cells (MDSCs) from
the
spleens of fB16_F1OL tumor-bearing A1KO mice and A1Tg mice were compared. The
results
are shown in Figure 18. Figure 18A shows a cell plot of Cdl lb-PE vs. GR1-APC
for A1Ko and
Al Tg derived cells. Figure 18B the average percentage of cdlb+/GR1+ (MDSC)
cells for
A1KO and A1Tg derived cells. Figure 18C shows the average as a percentage of
MDSC cells
for A1KO and A1Tg cells. Myeloid derived suppressor cells (MDSCs) playa major
role in
combating cancer growth and development. The data in Figure 18 shows that
apoAl alters the
phenotype of MDSCs into those that are associated with better cancer fighting
capabilities, and
improved overall outcomes. MDSCs are heterogeneous, made in bone marrow and
recruited to
tumor site and other organs such as spleen. High GR1+/CD11b+ MDSCs are
neutrophilic (help
tumors by expressing Mmp9, S100a8, S100a9, etc). Low GR1+ / CD11b+ expressing
MDScs
are more monocytic (not as pro-tumorigenic as neutrophils). In many tumors %
of high GR1+
(neutrophilic) correlates with tumor progression. ApoAl treatment (either
direct injection, or via
gene therapy as in this case with transgenic mice) reduces the high GR1+ MDSC
level. While
38
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
the present invention is not limited to any particular mechanism and an
understanding of the
mechanism is not necessary to practice the invention, these results further
suggest that one
mechanism that apoAl helps to reduce cancer development is through
immunomodulatory
effects on innate immune cells.
In another part of this Example, the effect of apoAl on angiogenisis was
measured
(results shown in Figure 19). This data shows that apoAl is anti-angiogenic,
another potential
mechanism through which it may promote its anti-cancer and anti-metastases
function (although
the present invention is not limited to any particular mechanism and an
understanding of the
mechanism is not necessary to practice the invention). Tumors can only grow so
much when fed
by diffusion from an adjacent capillary. Beyond a certain size, they need to
have new blood
vessels grow into them to feed the expanding nucleus of cells. Metastases
similarly need new
vessel growth to develop. In this Example, malignant melanoma cancer cells
were injected into
apoAl KO and TG mice. At approximately 1 week of age, tumors were excised and
the
numbers of vessels feeding the tumor cells directly quantified by microscopy.
Note that the
numbers of vessels is markedly reduced in the mice with appAl.
In another part of this Example, work was conducted that examined the role of
SRB1, the
classic HDL receptor, in the anti-cancer activities of apoAl and HDL. Mice
that lacked SRB1
(both heterozygous and homozygous) were injected with melanoma cells (B16F1OL-
luciferase).
As shown in Figure 20, animals that lack SRB 1 (both heterozygotes and
homozygotes) showed
protection from cancer growth, while the SRB1 containing mice (SRB1+/+) have a
greater rate
of tumor growth. While the present invention is not limited to any mechanism,
these results
appear to show two things. First, SRB 1, the classic HDL receptor, is not
playing a major
protective role in cancer mediated by apoAl. Second, since mice lacking SRB1
have higher
apoAl and HDL particle levels, these results strongly suggest that a HDL
receptor alternative to
SRB1 mediates the beneficial effects of apoAl and HDL on tumor growth and
metastases.
In other work, various monoclonal antibodies that target different forms of
oxapoAl were
used to screen malignant melanoma human cancer biopsy specimens. The results
are shown in
Figure 21.
In other work, immunohistochemistry on the human melanoma skin and normal skin
tissue was carried out on fresh frozen sections. The anti-human ox-apoAl mouse
monoclonal
antibody IOC5.2 was used at 10 ug/ml. Results are shown in Figure 22, where A-
C show ox-
39
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
apoAl staining; D-F show mouse IgGi control staining, and G-I show H&E
staining. These
results showed that antibodies specific to oxidized apoAl intensely stain
human malignant
melanoma tumor but not normal biopsy.
In other work, three mAbs shown to be specific for oxidized apoAI, were used
to stain
human malignant melanoma tumors. The oxidized apoAl specific antibodies were
each shown
to intensely stains multiple human malignant melanoma tumors but not normal
biopsy. Figure
23 shows the results for Mab IOG1.5, Figure 24 shows the results for Mab
IOC5.2, Figure 25
shows the results for Mab 4611.2, while Figure 26 shows the results of a Mab
control antibody.
EXAMPLE 4
ApoAl Inhibits Tumor Formation
The example provides further evidence that ApoAl inhibits tumor formation.
Mice deficient (SRB-1-/-) or heterozygous (SRB-1+/-) for HDL receptor, SRB-1,
were
injected with B16F1OL-luciferase (1x105 cells s.c., per flank) and tumor
growth was monitored
by IVIS Xenogen live imaging (A, n= number of mice). Results are shown in
Figure 27A.
Figure 27 B shows stimulation of allogenic T cell proliferation by splenic
dendritic cells (DCs)
isolated from naive or B16F1OL-luciferase tumor bearing mice of indicated
genotypes (n=
number of mice) 14 days post tumor cell injection. Data in Figure 27 C, where
n= number of
tumor injection sites, shows the terminal (day 21 post tumor injection; s.c.
bilaterally) tumor
volume measurements in B16F1OL-luciferase bearing NSG mice injected (s.c.,
away from the
site of tumor injection) every other day starting on day 1 post tumor
injection with ApoAl (20
mg/animal) or normal saline. Flow cytometry was performed on splenocytes from
mice
(n=number of animals) injected with normal saline (naive), B16F1OL-luciferase
(1x105 cells s.c.,
bilaterally) (27D) or injected with B16F1OL-luciferase cells at 4 separate
sites (1x105 cells s.c
per site) on the dorsal side (27E & F)) harvested on day 14 (D) or 12 (E & F)
post tumor
injection. Data points are mean +/-SEM.
The results in Figure 27 show: (i) The classic HDL receptor, SRB 1, is not
involved in
the therapeutic response from apoAl, since the absence of SRB1 is protective.
This is consistent
with elevated apoAl and HDLc levels in the SRB1 null mouse, and the apoAl
acting perhaps via
an alternative unknown receptor; (ii) The beneficial effect of apoAl is not
mediated by changes
in T cell proliferation by dendritic cells; (iii) Adaptive immunity, which is
impaired in the NSG
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
mice (lacking T cells, B cells and NK killer cells), is not involved in the
protective actions of
apoAl in cancer; (iv) In the absence of apoA1, there is an increase in CD 1
lb+Ly6C+, and
CD11bGR1+ high positive splenocytes, all indicative of adverse clinical
outcomes. Conversely,
genetic augmentation of apoAl levels (transgenic mouse) improves these adverse
markers; and
(v) There is a reduction in the number of tumor associated macrophages (as
monitored by F480+
antigen by flow cytometry) promoted by genetic enhancement of apoAl
production.
Angiogenesis was assessed in B16F1OL melanoma bearing mice 7 days post tumor
injection (s.c.,1x105 cells per flank). Tumor photographs were subjected to
VESGEN analysis
whereby color photomicrographs (Figure 28A) were converted to input vascular
binary images
(Figure 28B). The region of interest (ROI) representing the tumor mass (white
in B) defined the
perimeter of the tumor. The output of VESGEN was a series of color Generation
Maps (colored
vessels on black background) in which the largest diameter vessels were
defined as G1 (red),
with each subsequent smaller generation represented as G2 - G6 (C). Data in
Figures 28 D, E,
and F were generated from panel C and show number of blood vessels based on
vessel diameter
(D), total vessel area (E) and vessel length density (F). (G) Number of
vessels feeding directly
into the primary tumor was counted under a microscope where n= tumor injection
sites.
The data in Figure 28 collectively show that apoAl promotes an anti-angiogenic
(decreased number, cross sectional area, and length density) effect in cancer
model. This
biological effect is a mechanism which likely contributes to the observed anti-
tumor and anti-
metastases activity of apoAl therapy.
Primary subcutaneous B16F1OL tumors were harvested from Al KO and A1Tg tumor
bearing mice (8 animals per genotype) 7 days post injection (s.c.,1x105 cells
per flank). Total
tumor protein extracts were prepared and subjected to Western blotting.
Specific protein bands
were detected with Odyssey infrared imaging system with actin serving as
loading control.
Results are shown in Figure 29A. Figure 29B shows MMP-9 activity in tumor
extracts (in A)
was assayed using Quickzyme assay kit according to the manufacturer's
protocol. Pro-MMP-9
refers to total activity observed following chemical activation (APMA). Total
activity includes
the active enzyme (active MMP-9).
The data in Figure 29 shows that the amount and activity of MMP-9, a matrix
metalloprotease that is critical for tumor invasion and metasteses
development, is reduced by
apoAl (higher in the apoAI-KO, and reduced in the apoAl transgenic mouse).
This data also
41
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
shows that Calprotectin (S i 00A8/A9), an abundant protein in neoplastic tumor
cells and believed
to both serve as an adverse cancer marker and to promote inflammation-
associated cancer, is
markedly reduced by apoAI (higher in the apoAI-KO, and reduced in the apoAI
transgenic
mouse).
Figure 30 shows the effects of apoAl and HDL on B16F10 Melanoma wound healing-
migration and invasion through a basement membrane. B16F10 melanoma cells were
plated in 6
well dishes containing a polymer strip which was removed to create a clear
zone devoid of cells.
The wells were washed with serum free DMEM 3x and serum-free DMEM containing
the
indicated concentration of apo Al or HDL. In addition, 4ug/ml of Mitomycin C
(to block
cellular proliferation) was added to each well so that only migration/wound
healing would be
observed. Cells were photographed every 15 minutes using a 5x objective and
live imaging
(37C, 5% C02). Five fields per condition were examined. Images at time zero
and time at 45
hours were used to calculate the area of wound closure. Initial total area
devoid of cells for each
condition was determined using the image analysis program Image J (NIH) as was
the area
devoid of cells in each condition at 45 h after wounding. Area of wound
closure determined for
the control served as 100% and the relative wound healing for each condition
was determined by
dividing the area of wound closure for each condition by the area of wound
closure of the control
cells. The results are shown in Figure 30A. Data presented represent the mean
SD of at least
five photographic fields per condition. Significance was determined by two-
tailed student t test.
Representative photographs at time 0 and at 45 h after wounding are in the
panel to the right and
the experimental condition and concentration of apo Al or HDL is indicated.
These
experimental results are representative to two other identical experiments.
B16F10 melanoma cells 100,000 cells in 400u1 of serum-free DMEM containing
either
apo Al or HDL at the indicated concentration/ml were placed in the upper
chamber of a modified
Boyden chamber. Total protein in each well except for the control (Con) was
400ug and was
adjusted by the addition of ovalbumin to either the apo Al or HDL containing
wells if needed.
The bottom well of the Boyden chamber was filled with 0.8m1 of serum-free
DMEM. Cells were
incubated for 30h after which the upper chambers were "scrubbed to remove all
cells in the
upper well so that only cells which had invaded the 1% basement membrane and
moved to the
other side of the filter would be observed. Filters were then fixed and
stained with quick-fix.
Filters were photographed at 5X and the total area covered by the stained
cells was calculated by
42
CA 02802388 2012-12-10
WO 2011/159771 PCT/US2011/040471
the imaging core at CCF using Image Pro software. The results are shown in
Figure 30B. The
area covered by cells on the control filter was designated as 100% invasion
and cell areas were
determined for all other experimental conditions and compared to that of the
control cells.
Representative photographs of stained filters for each condition are below the
indicated condition
in Figure 30B. Data presented represent the mean SD of three filters per
condition.
Significance was determined by two-tailed student t test.
Collectively, the data in Figure 30 shows that HDL directly inhibits cancer
cell migration
and tissue invasion potential.
From the above description of the invention, those skilled in the art will
perceive
improvements, changes and modifications. Such improvements, changes and
modifications
within the skill of the art are intended to be covered by the appended claims.
All references,
publications, and patents cited in the present application are herein
incorporated by reference in
their entirety.
43
